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SUMMARY. Epigenetics as a cellular phenomenon represents a variety of cellular processes that regulate chromatin 
structure and gene expression without changing DNA sequence in a genome. Central epigenetic mechanisms are DNA 
methylation, posttranslational histone modifi cations and RNA interference. Epigenetic modifi cations interact with each 
other and create a unique epigenome extending throughout the cell, from DNA itself in the nucleus to the cell membrane, 
and in the context of a multicellular organism throughout a whole organism per se. Epigenetics functionally represents 
a complex molecular bridge that connects genotype and phenotype. Namely, a genome is a rigid structure of encoded 
inherited traits that determines all possibilities and limitations of a single cell phenotype capabilities, and therefore 
 phenotype of an individual as well. However, in the phenotype, at a given point at a particular site, only certain charac-
teristics encoded in the genome are expressed, and most preferably those that represent the best possible response of a 
cell and thus of the organism to the requirements of the cellular environment or the environment of the organism in toto. 
Epigenetic mechanisms are dependent on environmental stimuli and strongly affect phenotype properties. In this review, 
apart from introducing epigenetics, a number of concepts and evidence of interaction between the environment and 
genotype bridged by epigenetics are mentioned, with highlight on the infl uence of epigenetics on shaping the pheno-
types, especially in monozygotic twins.
Introduction to epigenetics
Epigenetics represents all cellular mechanisms lead-
ing to reversible changes in gene expression and chro-
matin structure that do not involve any change in a se-
quence of DNA per se (1). Indeed, “epigenetic” as a 
word literally means “around genetic sequence” and 
therefore has to be differentiated from genetics, well-
known genetic laws and genetic way of thinking over-
all. C.H. Wadington, a British scientist who in 1942 
tried to explain the process of a genotype manifesting 
itself in a phenotype of an individual cell and organism 
during developmental processes, has coined the term. 
He hypothesized and described epigenetics as a molec-
ular bridge between genotype and phenotype (2). Since 
then, many conceptual improvements and breakthroughs 
have been reached making epigenetics one of the most 
prominent and promising biological fi eld especially in 
the frame of biomedical research and cutting edge med-
ical practice (3–5).
DNA sequence, i.e. genome, by its function is a “li-
brary of inherited properties” and has to remain un-
changed throughout a lifespan of an individual organ-
ism, meaning single cells as well. Therefore, a genome 
of an individual has to be “solid” and prone to mecha-
nisms by which it may resist challenges of an environ-
ment. Many cellular mechanisms including DNA repair 
machinery have appeared throughout evolution with the 
only goal of fi ghting changes and degradation of inher-
ited features encoded in the DNA sequence. Conse-
quently, a genome is not the one that may provide to a 
cell, and therefore to an organism as a whole, adaptabil-
ity to ever-changing requirements of the environment or 
indeed to demands of a system such a multicellular or-
ganism is in fact. On the other hand, epigenetics repre-
sents a dynamic mediator between a genotype and cor-
responding phenotype. Epigenetics is an elegant system 
enabling to a cell, therefore an organism, to control ele-
ments of a genome i.e. different treats, to be reversibly 
projected in a phenotype of a specifi c cell according to 
organism demands and environmental challenges in a 
particular point of time and space (6). In short, stable 
genome encodes everything that a cell i.e. organism 
may be from fertilization to its death according to inher-
ited traits, while epigenome constantly “fi lters” all these 
possibilities and projects in the phenotype only those 
traits that presents the best possible answer to specifi c 
demands of pertaining organism and challenges of or-
ganism’s environment (7).
Apart of its crucial role in shaping organism’s pheno-
type, the power of epigenetics is best seen on a cellular 
level. Namely, in a multicellular organism, the epi-
genetics is indeed organizer of cell phenotype enabling 
to different embryonic and adult cells to express spe-
cifi c genes/traits that are required for the existence of 
each cell type. Since epigenome is mitotically inherit-
able, this phenotype is transferred to daughter cells 
from which can be transferred further on along the cell 
lineage, or eventually changed. Noteworthy, these 
changes can be transferred to the next generation of off-
spring if occur in germ cells that transfer specifi c epig-
enome to a zygote. Paramutation, bookmarking, im-
printing, gene expression, X chromosome inactivation, 
position effect, changeable disorder or phenotypic se-
verity, reprogramming, maternal attributes, carcinogen-
ic processes, teratogenic effects, genomic stability, het-
erochromatin states and cloning for example are known 
to involve epigenetic mechanisms (7–9).
Due to very loose defi nition, many various phenom-
ena have been suggested and are still debated to be part 
of epigenetics. Still, three of them are accepted as cen-
tral epigenetic mechanisms; DNA methylation, post-
translational histone modifi cations and RNA interfer-
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ence. These cellular phenomena are well described and 
are in the focus of almost every epigenetic research.
DNA methylation
First described and best understood epigenetic modi-
fi cation is certainly DNA methylation. It represents a 
quit simple biochemical process of covalent addition of 
methyl group to the 5th carbon atom of cytosine ring 
primarily in cytosine-guanine dinucleotide (CpG). 
Modifi ed by methylation, cytosine converts to 5-meth-
ylcytosine (5mC), also called the “fi fth base”. In mam-
mals, 60–90% of all CpGs are methylated with the ex-
ception of CpG rich areas of a genome referred to as 
CpG islands. Noteworthy, CpG islands frequently coin-
cide with gene promoters. DNA methylation in higher 
eukaryotes is associated with a dense chromatin envi-
ronment. Consequently, chromatin with hipermethyl-
ated DNA is rigid and usually embodies unexpressed 
genes (10, 11).
DNA methyltransferase (DNMTs) family enzymes 
perform methylation of DNA. DNMT1 functions as a 
maintenance methylase, copying the pre-existing meth-
ylation marks onto the new strand during replication of 
DNA. Therefore, DNMT1 is crucial for DNA methyla-
tion inheritance or so called epigenetic cell memory. 
DNMT3A and DNMT3B are de novo methyltransfer-
ases i.e. enzymes that are able to methylate previously 
unmethylated CpGs (12–14). Their main function is to 
guide the change of a cell phenotype in response to cell 
demands or environmental challenges. Other DNMT 
family members are DNMT2, involved in RNA meth-
ylation pathways, and DNMT3L which lacks catalytic 
activity but acts as a co-factor for the establishment of 
(non)CpG methylation (15, 16). In contrast to active 
processes of DNA methylation, DNA demethylation 
can be achieved both actively and passively. Passive 
DNA demethylation usually is a consequence of 
DNMT1 complete absence of function or at least its 
malfunction. Active DNA demethylation is performed 
by ten-eleven translocation (TETs) family enzymes 
that oxidize 5mC to 5-hydroxymethylcytosine (5hmC). 
Further on, 5hmC may be either passively depleted 
through DNA replication or actively reverted to cyto-
sine by thymine DNA glycosylase mediated base exci-
sion repair (17).
Apart mechanisms involved, DNA (de)methylation is 
a crucial force shaping the chromatin and presenting a 
genome into a phenotype. In fact, it is integrated in ev-
ery biological segment of individual’s life: reproduc-
tion, development, management of homeostasis, immu-
nity, healing and regeneration, behavior and social in-
teractions, ageing and in the end death of an organism 
itself (18–27).
Congruently to mentioned above, according to mod-
ern science it is quite unreasonable to expect any disor-
der or disease not to involve DNA methylation, at least 
at some extent (28). Maybe the best example of a dis-
ease driven by disruptions in DNA methylation is can-
cer. Indeed, more than enough evidence has been pre-
sented for describing cancer as a DNA methylation de-
pendent i.e. epigenetic disease (1, 6, 9, 29). In line with 
these fi ndings, a huge effort is put on developing new, 
or translating already existing, DNA methylation based 
diagnostic technology and therapeutic agents in every-
day medical practice (28, 30–34).
Histone modifi cations
Post-translational histone modifi cations (PTHM), 
sometimes not quite correctly referred to as histone 
code (35), are a group of primarily covalent additions 
and eliminations performed at histone tails in nucleo-
somes (36). All PTHM are executed by enzymes and 
are highly regulated. In general, PTHM shape the chro-
matin making it loose and prone to transcription or con-
densed and transcriptionally silenced (36). Still, com-
prehensive interpretation of all possible combinations 
of PTHM is far then simple and straightforward (35). 
PTHM change the behaviour of a chromatin not just by 
changing its chemistry and physics. They also recruit 
various DNA binding proteins as well as remodeling 
enzymes, which are further reorganizing a chromatin in 
a specifi c way infl uencing e.g. gene transcription or 
DNA repair, replication and recombination (35–38). 
Noteworthy, PTHM are closely related to DNA meth-
ylation, and these two epigenetic modifi cations tightly 
collaborate in organizing a genome and shaping the 
phenotype (39, 40).
One of the simplest, but seemingly most powerful 
PTHM is enzymatic addition or elimination of acetylic 
group to histone tail lysines. This PTHM is known as 
histone (de)acetylation. Histone acetylation neutralize 
the lysine’s positive charge. Thus, it becomes more neg-
ative. Since DNA is negatively charged as well, follow-
ing simple physical law DNA tries to “escape” the nu-
cleosom. This negative-DNA-negative-histone interac-
tion results in a loose chromatin, meaning revealed 
DNA sequence and more space in a chromatin to place 
DNA binding proteins such as transcription complex. 
On the other hand, by eliminating lysines acetylation, 
histone turns back to positive state and consequently 
trap DNA more tightly in a nucleosome. Structured like 
this, chromatin attracts proteins that further compact it 
leading to highly condensed and transcriptionally si-
lenced heterochromatin (41).
Histone (de)acetylation as an epigenetic mechanism, 
including biochemistry of enzymes involved and bio-
logical repercussions on genome status as well as cell 
phenotype, is mostly well understood. Regarding its im-
pact on a phenotype, histone (de)acetylation tails DNA 
methylation and is likewise integrated in every biologi-
cal segment of individual’s life (42).
Similar as with DNA methylation, histone (de)acety-
lation is under vivid attempt of translating it in clinical 
practice especially into a therapy of various human dis-
orders and diseases (33, 43–45).
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Contrary to histone (de)acetylation, other PTHM i.e. 
histone (de)methylations, (de)phosphorylation, deimi-
nation, ADP ribosylation, β-N-acetylglucosamine mod-
ifi cation, ubiquitylation and sumoylation along with 
histone tail clipping and histone proline isomerization 
are mostly yet to be comprehensively described and 
their biological impact further acknowledged (36).
RNA interference
RNA interference (RNAi) is the most recently dis-
covered main epigenetic modifi cation (46), for which 
The Nobel Prize in Physiology or Medicine was award-
ed in 2006. RNAi is probably the most dynamic epigen-
etic pathway prone to rapid turnovers (47) with notable 
impact on gene expression and therefore phenotype it-
self (48). The real power of RNAi upon shaping a phe-
notype is presented in the fact that it regulates the ex-
pression of around 60% of human genes (49).
Interestingly, it seems RNAi appeared as a primitive 
but affective cellular immune system mainly against vi-
ral genomes. Later on, at some point in eukaryotes evo-
lution, cells started to use the same mechanism not only 
for defending themselves from exogenous but rather 
endogenous genetic material. By chance, powerful epi-
genetic mechanism regulating presentation of traits 
from a genotype into a phenotype, came into being (50).
MicroRNA (miRNA) and small interfering RNA 
(siRNA), all in fact non-coding RNAs, are holders of 
RNA interference machinery and share many similari-
ties. Both are short duplex RNA molecules that exert 
gene silencing effects at the post-transcriptional level 
by targeting messenger RNA (mRNA). Both share same 
enzymatic machinery including proteins like DICER 
and ARGONAUT as well as RNA induced silencing 
complex (RISC) (51, 52). Still, crucial difference is that 
miRNAs have multiple mRNA targets regulating ex-
pression of many genes while siRNAs are highly spe-
cifi c focused on targeting precise mRNAs and conse-
quently expression of given genes (53).
As one of three canonical epigenetic modifi cation, 
RNAi seems to be involved in in each and every cellular 
phenomena. Consequently, RNAi disruptions may be 
found as drivers or passengers in various human dis-
eases (54, 55).
Environment, diet and lifestyle
The concept of diet, environment and lifestyle having 
impact on individual’s health and disease is not some-
thing new. Still, the scientifi c fact that all of them have 
strong and persistent molecular mechanisms to mess up 
with our genes and changing their expression in our 
phenotype is quite a novelty (7, 56), and not necessarily 
a good one (57). Added to mentioned that our decisions 
today regarding our lifestyle and environment may, fi rst 
by epigenetic reset followed by epigenetic inheritance 
through our germ cells, shape a phenotype of our off-
spring that have yet to come in more than hundred years 
from now (58), epigenetics suddenly sounds more like 
an evolutionary curse rather than interesting and pecu-
liar cellular phenomena. Well, although it all may 
sounds depressive, there is hope enclosed in the defi ni-
tion of epigenetics itself; it is reversible!
While the latest paragraph may sound more poetic 
than scientifi c, it actually represent a platform on which 
new concepts of human disease prevention and health 
support are tried to be built on. For example, sulfora-
phane (SFN) which is usually found in cruciferous veg-
etables such as broccoli, when consumed in a diet for 21 
days, suppressed the growth of human prostate cancer 
cells by 40% in male nude mice due to signifi cant de-
crease in histone deacetylase activity (59). In the same 
study, authors showed that in human subjects a single 
dose of 68 g BroccoSprouts inhibited histone deacety-
lase (HDAC) activity signifi cantly in peripheral blood 
mononuclear cells 3 and 6 hours following consump-
tion. These fi ndings provide evidence that one mecha-
nism through which SFN acts as a cancer chemopreven-
tive agent in vivo is through the inhibition of HDAC 
activity (59). Another research, designed as a year-long 
lifestyle modifi cation program, was conducted to medi-
ate cardiovascular risk through traditional risk factors 
and to investigate how molecular changes may contrib-
ute to long-term risk reduction. According to obtained 
results, authors concluded that successful and sustained 
modulation of gene expression through healthy lifestyle 
had benefi cial effects on vascular health and reduction 
of traditional risk factor profi les (60). In a pilot trial, 
stress reduction by transcendental meditation and ex-
tensive health education reduced patients’ blood pres-
sure by, according to authors, change in telomerase 
gene expression (61). Without discussing underlying 
molecular mechanisms, this study indisputably showed 
that in fact even by a simple meditation, one is able to 
change gene expression profi le with consequent pheno-
type modifi cation.
In short, one of the most exciting features of using 
epigenetics reversibility as well as dynamicity, through 
modulating lifestyle, environmental quality and diet es-
pecially, is a potential to offer cheap and responsive al-
ternative ways of preventing or curing diseases to which 
people are even hereditarily prone, including infl amma-
tion, diabetes, obesity, cancer, and neurodegenerative 
diseases for example (56).
Dizygotic twins
Considering epigenetics, dizygotic twins are perceived 
as (non)related individuals. They are much more studied 
in terms of traits in genotype and phenotype they share 
rather than those that differ them. Still, dizygotic twin 
share at least intrauterine environment as well as time 
and place of their existence if not organized differently 
(62, 63). This indeed cannot be ignored in term of com-
paring their health and disease statuses i.e. genotype rela-
tion to phenotype through epigenetics under environ-
mental infl uence, as described above (Figure 1).
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Monozygotic twins
Monozygotic twins provide a simple natural system 
for studying epigenetic plasticity as well as epigenetic 
role and power in shaping a phenotype including phe-
notypes of various disorders and diseases.
Although monozygotic twins are believed, not quite 
correctly, to share identical genome, they do not have to 
necessarily shape the same phenotype due to differenc-
es in exposed environment (Figure 2). This fact usually 
is not perceived for in utero period of twin’s life. In-
deed, it should. Namely, some of in utero events or con-
dition, such as unequal division of blastomeres or un-
even vascularization of the placenta, can be considered 
as non-shared early environmental exposures. It is well 
known that in utero growth restriction is in fact more 
pronounced in monozygotic twins. Differences in pla-
cental sharing and vascularization lead to occasional 
unequal blood and nutrient sharing, and, in about 15% 
of monozygotic twins diamniotic pregnancies result in 
twin-to-twin transfusion syndrome (64). Indeed, a ma-
jor difference in the intrauterine environment between 
monozygotic twins seems to be whether they share, or 
not, a common placenta. Using DNA methylation mea-
sured at >400,000 points in the genome, it was demon-
strated that the co-twins of monozygotic pairs (average 
age of 14) that shared a common placenta have more 
similar DNA methylation levels in blood throughout the 
genome relative to those with separate placentas. Func-
tional annotation of the genomic regions that show sig-
nifi cantly different correlation between monochorionic 
and dichorionic pairs found an over-representation of 
genes involved in the regulation of transcription, neuro-
nal development, and cellular differentiation. These re-
sults support the idea that prenatal environmental expo-
sures may have a lasting effect on an individual’s epi-
genetic landscape, and the potential for these changes to 
have functional consequences (65).
Monozygotic twins have a higher incidence of con-
genital heart disorders, and this noteworthy usually oc-
curs in one twin only (64). The higher risk nature of 
multiple pregnancies, their proclivity towards compli-
cations, and the twin-twin competition for maternal re-
sources increases the probability of a skewed environ-
ment affecting the twins in utero respectively (64), 
changing their phenotype regardless of sharing identical 
DNA sequence.
After birth, any non-shared environmental exposure, 
such as diet, smoking, toxin exposure and infection, as 
mentioned, may contribute towards twin discordance 
(64, 66, 67). One study examined the global and locus-
specifi c differences in DNA methylation and histone 
acetylation of a large cohort of monozygotic twins. It 
found that, although twins were epigenetically indistin-
guishable during the early years of life, older monozy-
gotic twins presented remarkable differences in their 
overall content and genomic distribution of methylated 
DNA and histone acetylation. These epigenetic differ-
ences affected their gene-expression portrait and pheno-
type overall (67).
Other study investigated if serum microRNAs (miRs) 
could explain discordance in non-alcoholic fatty liver 
disease (NAFLD). A cross-sectional analysis of a pro-
spective cohort study was performed in 40 twin pairs. 
All participants underwent a standardised research visit, 
liver MRI using proton-density fat fraction to quantify 
fat content, and miR profi ling of their serum. Results 
showed 6 concordant twin pairs for NAFLD, 28 concor-
dant for non-NAFLD while 6 were discordant for 
NAFLD. Within the six discordant twins, a panel of 10 
miRs differentiated the twin with NAFLD from the one 
without. Two of these miRs, miR-331-3p and miR-30c, 
were also among the 21 miRs that were different be-
tween NAFLD and non-NAFLD groups. Both miRs 
were highly heritable and highly correlated with each 
other suggesting involvement in a common mechanistic 
pathway. An interactome analysis of these two miRs 
showed seven common target genes. In conclusion, this 
research demonstrated that discordancy in liver fat con-
tent between the twins can be explained by miRs, and 
that this discordany seems to be heritable (68).
To make this (epi)genome environment interplay in 
shaping a phenotype more complicated, there are rea-
sonable evidences that already established phenotypic 
differences arising in twins could potentially cause 
shared exposures to have different effects, leading to 
further dissimilarity between the twins (67).
Organism’s phenotype present at a specifi c time relay 
on epigenetic responses to environmental and lifestyle 
challenges encountered by the organism itself. Still, this 
epigenetic response modelling the phenotype is possi-
ble only in the frame of inherited traits in the genome. 
Left side of the picture presents a (non)related individu-
als scenario, where organisms differ from each other by 
the inherited genome and therefore diapasons of possi-
ble epigenetic answers i.e. phenotypes, in the start. Rea-
sonably, this scenario will result in different phenotypes 
between individuals even if challenged by the similar 
environment or lifestyle. Epigenetic force shaping a 
phenotype is sometimes referred to as epigenetic drift 
(69). Right side of the picture presents monozygotic 
Figure 1. Benefi ts from twin studies in understanding epigenetics. Study-
ing discordant monozygotic twins, impact of environment on a pheno-
type by induced epigenome rearrangements of individuals with identical 
genome, may be elucidate. Taking in account differences in genomes, 
contrary may be identifi ed in concordant dizygotic twins sharing same 
traits. Combining these approaches, much can be understood about envi-
ronment conditioning genome presentation in phenotype by modulating 
epigenome.
DISCORDANT
MONOZYGOTIC
TWINS
(EPI)GENETIC
ENVIRONMENT
INTERPLAY
CONCORDANT
DIZYGOTIC
TWINS
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twins scenario where all individuals inherited the same 
genome and therefore diapasons of possible pheno-
types. Although it would be expected them to shape the 
same phenotype, they rather accumulate differences 
throughout their life, including in utero period. Devel-
oped differences in their phenotypes relay on either dif-
ferent epigenetic response to environment and lifestyle 
or even slightly but still present differences in environ-
ment and lifestyle, to which they are exposed, per se. 
Indeed, stronger differences in environment and life-
style encountered by the twins, stronger differences in 
their epigenome and therefore phenotypes will appear 
in time. We suggest referring to this epigenetic force as 
to epigenetic wedge since differences in shaping pheno-
types, although sharing the same genotype, are way 
more dramatic.
Conclusion
This review is just a preview indeed, of what can be 
reasonably expected from epigenetics to represents in 
fact for biology and biomedicine of monozygotic and 
dizygotic twins. Therefore, it should not surprise why 
authors from the fi eld highlight how an appreciation of 
epigenetics is missing from the understanding of twin 
phenotype organization phenomena i.e. biological pro-
cess of shaping different phenotypes originated from 
the same genotype (67).
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EPIGENETIKA BLIZANACA
Nino Sinčić
Pregled
Ključne riječi: epigenetika, genotip, fenotip, okoliš, blizanci
SAŽETAK. Epigenetika kao stanični fenomen, okuplja niz različitih staničnih procesa koji reguliraju strukturu kromatina 
te gensku ekspresiju bez zadiranja u sekvencu genoma. Središnji epigenetički procesi svakako su metilacija DNA, post-
translacijeke histonske modifi kacije i RNA interferencija. Navedene epigenetičke modifi kacije međusobno interagiraju 
i stvaraju jedinstveni epigenom koji se prostire kroz čitavu stanicu, od same DNA u jezgri do stanične membrane, a u 
kontekstu multicelularnog organizma kroz cijeli organizam per se. Epigenetika funkcionalno predstavlja kompleksan 
molekularni most koji spaja genotip i fenotip. Naime, genom je rigidna struktura ukodiranih naslijednih svojstava koji 
određuju sve mogućnosti i ograničenja fenotipa stanice i jedinke. Međutim, u fenotipu se u danom trenutku na određenom 
mjestu eksprimiraju samo određena svojstva kodirana u genomu, i to ponajprije ona koja predstavljaju najbolji mogući 
odgovor stanice, a time i organizma u cijelosti, na zahtjeve staničnog okoliša odnosno okoliša jedinke in toto. Epigenetički 
mehanizmi ovisni su o utjecaju okoliša i snažno utječu na isplovljavanje svojstava u fenotipu. U ovom preglednom radu, 
pored uvoda u osnove epigenetike, navodi se niz koncepata i dokaza o interakciji okoliša i genotipa preko epigenetike s 
naglaskom na spoznaje o utjecaju epigenetike na modeliranje fenotipa posebice monozigotnih blizanaca.
